<DOC>
	<DOCNO>NCT01090492</DOCNO>
	<brief_summary>The investigator propose daily administration PF-00489791 , phosphodiesterase inhibitor , reduce vasospasm improve symptom sign associate Primary Secondary Raynaud 's Phenomenon .</brief_summary>
	<brief_title>PF-00489791 For The Treatment Of Raynaud 's</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Active Raynaud 's Phenomenon Stable disease medication requirement previous two month For Secondary Raynaud 's Phenomenon subject , diagnosis scleroderma use American College Rheumatology criterion presence least 3/5 feature CREST syndrome sex Uncontrolled hypertension , diabetes mellitus , angina , use oral nitrate Smoking within 3 month smoke cessation use nicotine product Subjects currently take sildenafil , tadalafil vardenafil Subjects ulnar arterial occlusive disease show modified Allen test Pregnant breast feed consider pregnancy next 4 month Participation trial investigational drug within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Raynaud 's phenomenon</keyword>
	<keyword>vasospasm</keyword>
	<keyword>scleroderma</keyword>
	<keyword>systemic sclerosis</keyword>
	<keyword>CREST</keyword>
	<keyword>phosphodiesterase inhibitor</keyword>
</DOC>